Cue Biopharma is trading 11.95% down at $25.04, with no clear company-specific catalyst identified for September 2, 2026. - Investor relations’ latest listed company release dates to August 3 and concerns a CFO appointment and the CUE-221 regulatory filing. - The decline contrasts with biotechnology strength: XBI is up 2.75%, while broader U.S. indexes are higher. - The move appears isolated and unexplained; further disclosures may clarify it.